Analysis in progress
Initialising…
0%
complete
This report is still being assembled — sections appear as each stage finishes. It isn't final yet.
ATM
Final classification
VUS
ATM c.3332T>C · p.Leu1111Pro
ATM

PM2 (Supporting): gnomAD v4.1 allele frequency 3.098e-06 (0.00031%) is below the VCEP's 0.001% threshold, with no homozygotes observed.

Gene
ATM
Transcript
NM_000051.4
HGVS · transcript:coding
NM_000051.4:c.3332T>C
Consequence
N/A
GRCh38
chr11:108279538 T>C
GRCh37
chr11:108150265 T>C
Basis VUS: only PM2 (Supporting) is met — gnomAD v4.1 AF 3.098e-06 is below the 0.001% threshold — and no VCEP combination rule matched.
VUS: only PM2 (Supporting) is met — gnomAD v4.1 AF 3.098e-06 is below the 0.001% threshold — and no VCEP combination rule matched.
Classification rationale
PM2 VUS
ATM c.3332T>C

PM2 (Supporting): gnomAD v4.1 allele frequency 3.098e-06 (0.00031%) is below the VCEP's 0.001% threshold, with no homozygotes observed. Overall classification: Variant of Uncertain Significance — under the ClinGen HBOP ATM VCEP v1.5 ruleset, PM2_Supporting alone does not match any combination rule.

PM2 VUS
Gene diagram · NM_000051.4 · variants mapped to exon structure
ATM NM_000051.4
Fetching transcript structure from UCSC…
Applied criteria · 1 applied · 15 assessed
Applied · 1
Strength Supporting Moderate Strong Very strong
PM2 supporting Pathogenic
Met (Supporting): gnomAD v4.1 allele frequency 3.1e-06 (0.00031%) is below the VCEP's 0.001% supporting threshold.
gnomAD v4.1: total AF 3.09843e-06 (0.00031%) <= 0.001% threshold; 5/1613720 alleles, 0 homozygotesgnomAD v4.1: best subpopulation NFE AF 4.23788e-06 (0.00042%)gnomAD v2.1: AF 0 (0/250754 alleles)
Assessed · not applied
Pathogenic
PS1 Not assessed: insufficient evidence was available to evaluate this missense change against an established pathogenic variant at the same position.
PS3 Not met: a direct functional assay found the variant retains function (Sun et al.
PS4 Not met: no case-control or cohort enrichment study of this variant exists, so the PS4 requirements (p<=0.05 and OR>=2) cannot be met.
PM1 Not assessed: insufficient evidence was available to determine whether this position falls in a mutational hotspot or critical domain.
PM3 Not assessed: no evidence places this variant in an affected A-T proband (all ClinVar submissions are VUS), so no PM3 points could be accrued.
PM5 Not assessed: insufficient evidence was available to determine whether a different pathogenic variant occurs at the same codon.
PP1 Not assessed: no segregation or pedigree evidence was available — zero informative meioses — so no PP1 strength could be assigned.
PP2 Not assessed: insufficient evidence was available to evaluate whether missense variants in ATM are a common disease mechanism.
PP3 Not met: REVEL 0.644 is below the >0.7333 PP3 threshold, and SpliceAI max delta 0.01 is below 0.2.
Benign
BA1 Not met: gnomAD v4.1 grpmax FAF 1.24e-06 (0.000124%) is about 4000-fold below the 0.5% BA1 threshold.
BS1 Not met: gnomAD v4.1 grpmax FAF 1.24e-06 (0.000124%) is about 400-fold below the 0.05% BS1 threshold.
BS3 Not assessed: the sole functional assay (Sun et al.
BP1 Not assessed: insufficient evidence was available to evaluate whether this variant lies outside a critical protein domain.
BP2 Not assessed: no unaffected carrier in trans with a pathogenic variant was documented, so no BP2 points could be accrued.
BP4 Not met: REVEL 0.644 is above the <=0.249 BP4 threshold; missense variants are evaluated on the REVEL sub-path only.
N/A · 12 PVS1 · PS2 · PM4 · PM6 · PP4 · PP5 · BS2 · BS4 · BP3 · BP5 · BP6 · BP7
Research & evidence
Population frequency
gnomAD v4.1 screenshot
gnomAD v4.1
gnomAD v2.1 screenshot
gnomAD v2.1
v4.1
This variant is present in gnomAD v4.1 (AF= 3.09843e-06; MAF= 0.00031%, 5/1613720 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 4.23788e-06; MAF= 0.00042%, 5/1179836 alleles, homozygotes = 0); grpmax FAF= 1.24e-06.
v2.1
This variant is present in gnomAD v2.1 (AF= 0; MAF= 0.00000%, 0/250754 alleles, homozygotes = 0) and has highest observed frequency in the African/African American population (AF= 0; MAF= 0.00000%, 0/16228 alleles, homozygotes = 0).
🇨🇦 CA
Absent from gnomAD-Canada v1.0.
Allele frequency by ancestry
three datasets · side by side
gnomAD v4.1
0.00031% · 5 / 1,613,720
0 hom · FAF 0.00012%
European (non-Finnish)
5 / 1,179,836
0.00042%
+ 9 not observed (Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American)
gnomAD v2.1
Absent · 0 / 250,754
0 hom
Not observed in any ancestry group.
+ 8 not observed (African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), European (non-Finnish), Remaining individuals, South Asian)
gnomAD Canada 🇨🇦
Absent · 0 / ?
0 hom
Not observed in any ancestry group.
ClinVar screenshot
ClinVar
This variant has been reported in ClinVar as Uncertain significance (7 clinical laboratories). (ClinVarID = 230062)
SpliceAI screenshot
In silico
SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.644. BayesDel score = 0.101685.
Functional / OncoKB screenshot
Functional Unknown Oncogenic Effect
OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ATM, a kinase involved in the DNA damage response, is mutated in various solid and hematologic malignancies.
OncoKB ↗
COSMIC screenshot
COSMIC
Cancer hotspots screenshot
Cancer hotspots
Somatic evidence Not in COSMIC / hotspots
COSMIC
This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV99592016, n = 1 times).
Hotspots
This variant does not lie in a statistically significant hotspot.
Sources & reference links
9Sources
CSpec VCEP
ClinVar
gnomAD v2.1
gnomAD v4.1
gnomAD-Canada
SpliceAI
OncoKB
COSMIC
Cancer hotspots
Triaged references · 7 PMIDs not cited in assessment
25741868 ↗ Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. CLINVAR
34242744 ↗ Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. CLINVAR
40580951 ↗ Functional assessment of all ATM SNVs using prime editing and deep learning. CLINVAR
20301425 ↗ BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. CLINVAR
24366402 ↗ Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force. CLINVAR
24432435 ↗ PMID 24432435 CLINVAR
31479213 ↗ PMID 31479213 CLINVAR